**Background**
Angiogenesis, the process of forming new blood vessels from pre-existing ones, is a critical requirement for the growth and metastasis of solid tumors. This process is primarily driven by the vascular endothelial growth factor (VEGF) family and its corresponding receptors, including VEGFR-1 (Flt1), VEGFR-2 (KDR), and VEGFR-3 (Flt4). Overexpression of these receptors and their ligands often leads to uncontrolled vessel sprouting, providing tumors with the necessary nutrients and oxygen to proliferate. Consequently, targeting the VEGF receptor tyrosine kinase pathway has become a cornerstone in the development of anti-angiogenic therapies for various malignancies. In this context, we will introduce a potent multi-kinase inhibitor used in Cediranib Cancer research – Cediranib.
**Definition**
Cediranib is a highly potent, orally available inhibitor of VEGFR with IC50 values of <1 nM for Flt1, <3 nM for KDR, 5 nM for Flt4, 5 nM for PDGFRβ, 36 nM for PDGFRα, and 2 nM for c-Kit. **In Vitro and In Vivo Studies** The Cediranib description highlights its efficacy in disrupting vascular signaling. In terms of Cediranib in vitro activity, the compound inhibits VEGF-stimulated proliferation and KDR phosphorylation in human umbilical vein endothelial cells with IC50 values of 0.4 nM and 0.5 nM, respectively. Furthermore, in a fibroblast/endothelial cell coculture model of vessel sprouting, Cediranib reduces vessel area, length, and branching at subnanomolar concentrations.
Regarding Cediranib in vivo efficacy, once-daily oral administration of the compound ablates experimental VEGF-induced angiogenesis and inhibits physiologic processes dependent on neovascularization, such as endochondral ossification in bone and corpora luteal development in the ovary. In athymic mice bearing established human tumor xenografts—including colon, lung, prostate, breast, and ovary models—the growth of tumors was inhibited in a dose-dependent manner. Specifically, chronic administration of 1.5 mg/kg per day produced statistically significant inhibition across all models. Histologic analysis of Calu-6 lung tumors revealed a reduction in microvessel density within 52 hours, which increased with the duration of treatment, indicating significant vascular regression within the tumors. In conclusion, Cediranib is a potent VEGFR inhibitor that effectively suppresses angiogenesis and inhibits tumor growth across multiple cancer types.
Keywords
Cediranib, 857036-77-2, AZD-2171, AZD2171, AZD 2171, VEGFR, Autophagy, PDGFR, Vascular endothelial growth factor receptor, Platelet-derived growth factor receptor, Inhibitor, inhibitor, inhibit
References